New international guidelines stress early detection and treatment of acute pulmonary embolism (PE), a life-threatening blood clot in the lungs.
A new clinical classification system is presented to define the severity of an acute PE and assist in developing adult treatment strategies.
About the National Blood Clot Alliance: The National Blood Clot Alliance is the nation’s leading nonprofit voluntary health organization dedicated to advancing the prevention, early diagnosis, and ...
News-Medical.Net on MSN
New guidelines outline comprehensive care for acute pulmonary embolism
Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical. Comprehensive ...
DALLAS and WASHINGTON - Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is ...
The 2026 AHA/ACC guidelines introduce a five-tier Acute PE Clinical Category system to stratify severity and guide treatment decisions. Mechanical thrombectomy receives a Class 2a recommendation for ...
Women are less likely than men to receive thrombectomy. New data show the treatment can improve function and quality of life.
The first clinical practice guideline on acute pulmonary embolism (PE) from the American Heart Association and the American ...
Stories this month focused on TAVI in low-risk patients, statin safety, the burden of CKM syndrome in the US, and more.
Everyday Health on MSN
Estrogen Patches Are in Short Supply — Is There a Workaround?
Rising interest in hormone therapy for premenopause and menopause symptoms has led to estrogen patch shortages. Experts share strategies to try to find this medication or stretch out what you have.
To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1- 800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. INDICATION WINLEVI (clascoterone) cream 1% is an ...
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results